Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 5/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1014871 | 0.92 | SERPINE1 (0.51) | SERPINE1MAPTPOLBGAAMEN1 | |
| SCHEMBL1013719 | 0.89 | SERPINE1 (0.44) | SERPINE1RXFP1MAPTPOLBGAA | |
| SCHEMBL1015621 | 0.89 | SERPINE1 (0.50) | SERPINE1RXFP1MAPTPOLBNR4A2 | |
| SCHEMBL1016668 | 0.88 | RXFP1 (0.40) | RXFP1MAPTPOLBGAAMEN1 | |
| SCHEMBL17530241 | 0.87 | SERPINE1 (0.52) | SERPINE1MAPTPOLBGAAMEN1 | |
| SCHEMBL1015797 | 0.86 | SERPINE1 (0.50) | SERPINE1RXFP1MAPTPOLBGAA | |
| SCHEMBL1013661 | 0.81 | SERPINE1 (0.59) | SERPINE1MAPTPOLBGAAALDH1A1 | |
| SCHEMBL1013740 | 0.80 | SERPINE1 (0.51) | SERPINE1MAPTGAAMEN1KMT2A | |
| SCHEMBL1015677 | 0.79 | KDM4E (0.44) | SERPINE1MAPTPOLBGAAMEN1 | |
| SCHEMBL1015109 | 0.78 | SERPINE1 (0.57) | SERPINE1RXFP1NR4A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415479-B2 | Inhibitor of plasminogen activator inhibitor-1 | RENASCIENCE CO., LTD. (JP) | 2013-04-09 | — | — | US | disclosed |
| US-20110112140-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | RENASCIENCE CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| EP-2272822-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | Renascience CO., LTD. (JP) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112140-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | SERPINE1, SERPINB1, SERPINC1 | SERPINE1 1/4885RXFP1 1415/4885MAPT 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.